Tweed Hospital
Welcome,         Profile    Billing    Logout  
 4 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chorlton, Charmayne
P3BEP, NCT02582697 / 2015-003060-37 / ACTRN12613000496718: Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Recruiting
3
500
US, RoW
Bleomycin (active name: Bleomycin Sulfate), Blenamax (Aspen), DBL Bleomycin Sulphate (Willow Pharmaceuticals Pty Limited), Bleo Powder for injection (Hospira), Etoposide, DBL Etoposide Injection (Hospira), Etopophos (Bristol-Myers Squibb), Etoposide (Pfizer), Etoposide Ebewe (Sandoz), Cisplatin, Cisplatin Ebewe (Sandoz), Cisplatin injection (Pfizer), DBL Cisplatin Injection (Hospira), Pegylated G-CSF (Pegfilgrastim), Neulasta Syringe with Automatic Needle Guard (Amgen), Filgrastim, Neupogen (Amgen), Nivestim (Hospira), Tevagrastim (Teva Pharma Australia Pty Ltd), Zarzio (Sandoz)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cambridge University Hospitals NHS Foundation Trust, Cancer Trials Ireland, Children's Oncology Group, Dana-Farber Cancer Institute, University of Southern California
Intermediate and poor-risk metastatic germ cell tumours (GCTs)
02/22
07/23
Srivastav, Ratnesh
P3BEP, NCT02582697 / 2015-003060-37 / ACTRN12613000496718: Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Recruiting
3
500
US, RoW
Bleomycin (active name: Bleomycin Sulfate), Blenamax (Aspen), DBL Bleomycin Sulphate (Willow Pharmaceuticals Pty Limited), Bleo Powder for injection (Hospira), Etoposide, DBL Etoposide Injection (Hospira), Etopophos (Bristol-Myers Squibb), Etoposide (Pfizer), Etoposide Ebewe (Sandoz), Cisplatin, Cisplatin Ebewe (Sandoz), Cisplatin injection (Pfizer), DBL Cisplatin Injection (Hospira), Pegylated G-CSF (Pegfilgrastim), Neulasta Syringe with Automatic Needle Guard (Amgen), Filgrastim, Neupogen (Amgen), Nivestim (Hospira), Tevagrastim (Teva Pharma Australia Pty Ltd), Zarzio (Sandoz)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cambridge University Hospitals NHS Foundation Trust, Cancer Trials Ireland, Children's Oncology Group, Dana-Farber Cancer Institute, University of Southern California
Intermediate and poor-risk metastatic germ cell tumours (GCTs)
02/22
07/23
BCG+MMC, NCT02948543: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer

Active, not recruiting
3
501
Europe, RoW
Bacillus of Calmette-Guerin (BCG), OncoTICE, ImmuCYST, TheraCys, Mitomycin (MM)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Australia
Bladder Cancer
12/24
12/24
Ku, Matthew
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
COALITION, NCT04914741: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting
1/2
80
RoW
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Glofitamab, RO7082859, CD20-TCB, Polatuzumab vedotin
Peter MacCallum Cancer Centre, Australia, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
12/23
07/25
Campher, Matthys
No trials found

Download Options